KRAS and neoplasm: In multivariable Cox models adjusted for established clinicopathological factors including age, sex, tumor location, histological type, pathological stage, receipt of adjuvant chemotherapy, and MMR/MSI status, KRAS G12A remained an independent adverse prognostic factor for both endpoints, in both the FMU cohort (RFS: adjusted HR, 5.23; 95%CI, 1.50–14.11; p = 0.003; OS: adjusted HR, 10.64; 95%CI, 2.39–34.00; p < 0.001) and in the AC-ICAM cohort (RFS: adjusted HR, 5.13; 95%CI, 1.15–16.44; p = 0.013; OS: adjusted HR, 3.83; 95%CI, 1.08–10.61; p = 0.018).